

## Technology Advisory Committee B Interests Register Appraisal of difelikefalin for treating pruritus in people having haemodialysis [ID3890] Publication Date: 17/05/2023.

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
George Lancaster, Policy Manager	Patient Expert	Indirect – financial	George has declared as he is part of the kidney research organisation has received funding from Vifor for clinical research project.	N/A	08/02/23	N/A	It was agreed that his declaration would not prevent George Lancaster from providing expert advice to the committee
Kieran McCarthy, National Programme of Care Manager	Clinical Expert	Direct financial	Kieran declared he was the national coordinating investigators for one of the relevant researches in the topic called CDK	N/A	08/02/23	N/A	It was agreed that his declaration would not prevent Kieran McCarthy from providing expert advice to the committee

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Faizan Awan, Patient representative	Patient Expert	Direct financial interest	Faizwan declared he is a paid patient advisor role with CSL Vifor	N/A	08/02/23	N/A	It was agreed that his declaration would not prevent Faizan Awan from providing expert advice to the committee
Indranil Dasgupta, Policy Manager	Clinical expert	Non direct financial interest	Indranil declared he has received honorarium and travel costs to attend a Global Advisory Board on the role of difelikefalin in CKD associated pruritus in Paris on 20/06/2022	N/A	08/02/23	N/A	It was agreed that his declaration would not prevent Indranil Dasgupta from providing expert advice to the committee

## **GUIDANCE NOTES FOR COMPLETION OF THE INTERESTS REGISTER**

**Relevant dates:** Detail here the date the interest arose and when it ceased, if applicable. For example, if an individual has ceased to hold shares or undertake relevant private practice.